Brazionis, Laima
Quinn, Nicola
Dabbah, Sami
Ryan, Chris D.
Møller, Dennis M.
Richardson, Hilary
Keech, Anthony C.
Januszewski, Andrzej S. http://orcid.org/0000-0003-0583-3717
Grauslund, Jakob
Rasmussen, Malin Lundberg
Peto, Tunde
Jenkins, Alicia J.
Funding for this research was provided by:
National Health and Medical Research Council (GNT1079864)
Article History
Received: 3 October 2022
Revised: 6 January 2023
Accepted: 4 February 2023
First Online: 18 February 2023
Declarations
:
: All procedures performed in the case study by the authors involving human participants were in accordance with the ethical standards of the Regional Scientific Ethical Committee of Southern Denmark and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all individual human participants included in the study. This article does not contain any studies with animals performed by any of the authors.
: Authors A. Jenkins, T. Peto, L. Brazionis, and A. Januszewski are investigators on an investigator initiated trial of fenofibrate in adults with diabetic retinopathy (the FAME-1 Eye trial) which is funded by the Australian NHMRC, the Juvenile Diabetes Research Foundation (JDRF) Australia and Abbott (EU). A. Jenkins, L. Brazionis, A. Januszewski, and N. Quinn have published research related to the FIELD trial of fenofibrate in diabetes retinopathy.